MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Argos Therapeutics Company Profile (NASDAQ:ARGS)

Consensus Ratings for Argos Therapeutics (NASDAQ:ARGS) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.57 (133.67% upside)

Analysts' Ratings History for Argos Therapeutics (NASDAQ:ARGS)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Piper JaffrayReiterated RatingOverweight$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Needham & Company LLCReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Roth CapitalBoost Price TargetBuy$11.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Stifel NicolausLower Price TargetBuy$16.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$17.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015MLV & Co.Set Price TargetBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Argos Therapeutics (NASDAQ:ARGS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q1($0.56)($0.57)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.88)($0.84)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.92)($0.97)$158.35 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.80)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.80)($0.89)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2015Q314($0.73)($0.83)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.65)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.60)($0.61)$1.27 million$1.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.46)($1.05)$1.26 million$0.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($2.63)($36.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Argos Therapeutics (NASDAQ:ARGS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.70)($0.54)($0.62)
Q2 20162($0.58)($0.52)($0.55)
Q3 20162($0.70)($0.52)($0.61)
Q4 20162($0.60)($0.51)($0.56)
(Data provided by Zacks Investment Research)
Dividend History for Argos Therapeutics (NASDAQ:ARGS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Argos Therapeutics (NASDAQ:ARGS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/16/2015Andrei Vladimirovich PetrovDirectorBuy5,000$1.80$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Joan WinterbottomInsiderBuy250$1.83$457.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Alexey Alexandrovic VinogradovDirectorBuy2,000$2.15$4,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Jeffrey D AbbeyCEOBuy1,000$3.89$3,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Holle Philippe Marie Marce VanDirectorBuy10,000$4.28$42,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Holle Philippe Marie Marce VanDirectorBuy12,000$6.27$75,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Holle Philippe Marie Marce VanDirectorBuy5,000$6.26$31,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Jean LamarreDirectorBuy2,500$6.14$15,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Jeffrey D AbbeyCEOBuy5,500$4.75$26,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Deventer Sander VanDirectorBuy36,416$8.00$291,328.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014International S PharmstandardMajor ShareholderBuy1,275,000$8.00$10,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Argos Therapeutics (NASDAQ:ARGS)
DateHeadline
06/27/16 07:18 AMNext Weeks Broker Price Targets For Argos Therapeutics Inc (ARGS) - Fiscal Standard
06/27/16 07:11 AMArgos Therapeutics Added to the Russell 2000® Index - [at noodls] - DURHAM, N.C., June 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies ...
06/26/16 07:40 AMAre Analysts Bearish Argos Therapeutics Inc (NASDAQ:ARGS) After Last Week? - Press Telegraph
06/24/16 02:34 PMNew Broker Ratings For Argos Therapeutics Inc (ARGS) - FTSE News
06/22/16 02:35 PMArgos Therapeutics Inc (ARGS) Updated Price Targets - FTSE News
06/21/16 07:20 AMRecently Issued Stock Ratings For Argos Therapeutics Inc (ARGS) - Fiscal Standard
06/20/16 01:02 PMETF’s with exposure to Argos Therapeutics, Inc. : June 20, 2016 -
06/19/16 02:32 PMArgos Therapeutics Inc (ARGS) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 06:34 AMArgos Therapeutics Inc with Dr. Robert Figlin Call scheduled for 4:30 pm ET today -
06/16/16 04:25 AMArgos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies - GlobeNewswire (press release)
06/15/16 07:38 PMArgos Therapeutics (ARGS) Enters Immunotherapies Partnership with Adaptive Biotechnologies - StreetInsider.com
06/15/16 11:30 AMDurham's Argos to learn more about how its drugs affect immune system -
06/15/16 07:21 AMIDMC clearance unlocks $30 million for Argos Therapeutics Inc. (NASDAQ: ARGS) - Scibility Media
06/15/16 07:00 AMArgos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies - [GlobeNewswire] - DURHAM, N.C., June 15, 2016-- Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based ...
06/14/16 07:43 AMNASDAQ Losers: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), Argos Therapeutics, Inc. (NASDAQ:ARGS ... - KC Register
06/14/16 07:43 AMArgos Therapeutics (ARGS) Says IDMC Recommends AGS-003 Phase 2 ADAPT Trial Continue; Second Financing ... - StreetInsider.com
06/13/16 09:56 AMDurham's Argos hears positive news from independent safety board -
06/13/16 07:48 AMARGOS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote -
06/13/16 07:19 AMIndependent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review - [at noodls] - Positive outcome triggers the second tranche of the Company's previously announced financing agreement Argos Therapeutics to host conference call with the trial's co-principal investigator, Dr. Robert ...
06/11/16 10:43 AMTrend Of Rating Given To Argos Therapeutics, Inc. (NASDAQ:ARGS) - Investor Newswire
06/08/16 08:57 PMArgos Therapeutics to Participate in Jefferies 2016 Healthcare Conference - GlobeNewswire (press release)
06/06/16 07:45 PMMarket News: Big Moving Stocks – HMNY, VBLT, CYCC, ARGS, CETX, ONTX, TIL
06/03/16 02:09 PMETF’s with exposure to Argos Therapeutics, Inc. : June 3, 2016 -
06/03/16 11:03 AMBroker Watchlist: Argos Therapeutics Inc (ARGS) - Share Trading News
06/02/16 11:15 AMEarnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy? - Nasdaq - Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?NasdaqArgos Therapeutics, Inc.ARGS is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision ...and more »
06/02/16 07:37 AMEarnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy? -
06/01/16 02:38 PMBuy, Sell Or Hold Rating For Argos Therapeutics Inc (ARGS)? - Share Trading News - Buy, Sell Or Hold Rating For Argos Therapeutics Inc (ARGS)?Share Trading NewsArgos Therapeutics Inc has a 50 day moving average of 6.89 and a 200 day moving average of 4.70. The stock's market capitalization is 139.48M, it has a 52-week low of 1.61 and a 52-week high of 13.97. The share price of the company (ARGS) was up ...Argos Therapeutics, Inc. (NASDAQ:ARGS) Posts Quarterly EPS Of $-0.5671 From Continuing OperationsEnterprise LeaderArgos Therapeutics, Inc. (NASDAQ:ARGS): Company Rating and Earnings RoundupFranklin IndependentArgos Therapeutics Inc (NASDAQ:ARGS) Given Average Recommendation of “Buy” from BrokeragesLet Me Know About ThisThe Postall 5 news articles »
06/01/16 12:23 PMArgos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 02:36 PMArgos Therapeutics Inc (NASDAQ:ARGS) Given Average Recommendation of “Buy” from Brokerages - Let Me Know About This - Argos Therapeutics Inc (NASDAQ:ARGS) Given Average Recommendation of “Buy” from BrokeragesLet Me Know About ThisArgos Therapeutics logo Shares of Argos Therapeutics Inc (NASDAQ:ARGS) have received a consensus recommendation of “Buy” from the nine research firms that are presently covering the company. Nine research analysts have rated the stock with a buy ...Argos Therapeutics, Inc. (NASDAQ:ARGS) increased 7.19%: Amgen Inc. (NASDAQ:AMGN), MTS Systems Corporation ...KC Registerall 2 news articles »
05/31/16 10:10 AMStock Review and Earnings Check on Argos Therapeutics, Inc. (NASDAQ:ARGS) - HNN - Stock Review and Earnings Check on Argos Therapeutics, Inc. (NASDAQ:ARGS)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Argos Therapeutics, Inc. (NASDAQ:ARGS) to report quarterly EPS of $-0.4. The company's next earnings report is expected to be published ...and more »
05/31/16 10:10 AMArgos Therapeutics, Inc. (NASDAQ:ARGS) increased 7.19%: Amgen Inc. (NASDAQ:AMGN), MTS Systems Corporation ... - KC Register - Argos Therapeutics, Inc. (NASDAQ:ARGS) increased 7.19%: Amgen Inc. (NASDAQ:AMGN), MTS Systems Corporation ...KC RegisterOn 12 May, Argos Therapeutics, Inc. (NASDAQ:ARGS) reported that, Net loss for the three months ended March 31, 2016 was $12.8 million, or $0.57 per share, compared to a net loss of $17.5 million, or $0.89 per share, for the same period in 2015. Revenue ...
05/30/16 10:35 PMArgos Therapeutics, Inc. (NASDAQ:ARGS) Daily Sentiment Score Of 0.31 - Investor Newswire - Argos Therapeutics, Inc. (NASDAQ:ARGS) Daily Sentiment Score Of 0.31Investor NewswireArgos Therapeutics, Inc. (NASDAQ:ARGS) has a daily sentiment score of 0.31. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The content ...and more »
05/30/16 10:35 PMArgos Therapeutics, Inc. (NASDAQ:ARGS) Daily Sentiment Score Of 0.31 - Investor Newswire - Argos Therapeutics, Inc. (NASDAQ:ARGS) Daily Sentiment Score Of 0.31Investor NewswireArgos Therapeutics, Inc. (NASDAQ:ARGS) has a daily sentiment score of 0.31. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The content ...and more »
05/29/16 11:10 AMHow Analysts Rated Argos Therapeutics Inc (NASDAQ:ARGS) Last Week? - HNN - How Analysts Rated Argos Therapeutics Inc (NASDAQ:ARGS) Last Week?HNNOut of 6 analysts covering Argos Therapeutics (NASDAQ:ARGS), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Argos Therapeutics has been the topic of 4 analyst reports since November 16, 2015 according to StockzIntelligence Inc.
05/26/16 10:29 AMArgos Therapeutics, Inc. (NASDAQ:ARGS) EPS Estimate At $-0.4 - Investor Newswire - Argos Therapeutics, Inc. (NASDAQ:ARGS) EPS Estimate At $-0.4Investor NewswireThe EPS projection of Argos Therapeutics, Inc. (NASDAQ:ARGS) for quarter ended 2016-09-30 is $-0.4. A week earlier, the EPS target was $-0.4 against target of $-0.4, a month earlier. This target stood at $-0.4 60 days ago against estimate of $-0.4 90 ...and more »
05/26/16 10:29 AMInsiders Are Gradually Buying Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Hints and News - Insiders Are Gradually Buying Argos Therapeutics, Inc. (NASDAQ:ARGS)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Argos Therapeutics, Inc. (NASDAQ:ARGS) have increased their position in the stock by 1.08% over the past 6 months. Insiders now own 4.70% of total outstanding shares. There are both legal and illegal ...and more »
05/25/16 12:31 PMEarnings Review and Stock Rundown for Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Hints and News - Earnings Review and Stock Rundown for Argos Therapeutics, Inc. (NASDAQ:ARGS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Argos Therapeutics, Inc. (NASDAQ:ARGS) to ...and more »
05/25/16 12:04 PMARGOS THERAPEUTICS INC Financials -
05/24/16 12:59 PMToday Argos Therapeutics Inc Stock Crashes - Wall Street Hints and News - Today Argos Therapeutics Inc Stock CrashesWall Street Hints and NewsThe stock of Argos Therapeutics Inc (NASDAQ:ARGS) is a huge mover today! The stock decreased 3.02% or $0.18 during the last trading session, hitting $5.78. About 129,723 shares traded hands. Argos Therapeutics Inc (NASDAQ:ARGS) has declined ...
05/21/16 12:21 PMRevenue Update on Argos Therapeutics Inc(NASDAQ:ARGS) - Trade Calls - Revenue Update on Argos Therapeutics Inc(NASDAQ:ARGS)Trade CallsArgos Therapeutics Inc(NASDAQ:ARGS) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Company reported revenue of $146.43K. Analysts estimated a revenue of $180.00K. Earnings per ...
05/18/16 01:04 PMShare Recap and Earnings Focus on Argos Therapeutics, Inc. (NASDAQ:ARGS) - Wall Street Hints and News - Share Recap and Earnings Focus on Argos Therapeutics, Inc. (NASDAQ:ARGS)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Argos Therapeutics, Inc.and more »
05/16/16 04:44 PMARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report -
05/13/16 11:37 AMEdited Transcript of ARGS earnings conference call or presentation 12-May-16 8:30pm GMT -
05/12/16 04:27 PMArgos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights - [at noodls] - - Entered into Equity Financing for Up to $60 million - - Phase 3 ADAPT trial of AGS-003 in Metastatic Renal Cell Carcinoma On Track for Upcoming Review by Independent Data Monitoring Committee - - Dr. ...
05/12/16 03:35 PMARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex -
05/12/16 03:30 PMArgos Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today -
05/12/16 03:26 PMArgos Therapeutics reports 1Q loss -
05/12/16 03:19 PM4:19 pm Argos Therapeutics reports Q1 EPS of ($0.57) vs ($0.57) Capital IQ Consensus Estimate -
05/12/16 07:05 AMCD International Begins Turning Investor’s Heads - With CDII trading near a bottom we believe this is a particularly interesting time to enter the stock. A few other companies we’ve been looking at include: Ceragon Networks Ltd. (CRNT), Argos Therapeutics, Inc. (ARGS), and KemPharm, Inc. (KMPH).
05/12/16 06:07 AMQ1 2016 Argos Therapeutics Inc Earnings Release - After Market Close -
About Argos Therapeutics

Argos Therapeutics logoArgos Therapeutics, Inc. (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. The Company is also developing AGS-004, its second Arcelis-based product candidate, for the treatment of Human Immunodeficiency Virus (HIV). The Company is conducting a Phase III clinical trial of AGS-003 plus sunitinib/targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA) with the Food and Drug Administration (FDA). The Company has completed three clinical trials of AGS-004. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate personalized immunotherapies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARGS
  • CUSIP:
Key Metrics:
  • Previous Close: $5.51
  • 50 Day Moving Average: $6.10
  • 200 Day Moving Average: $5.00
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $140.85M
  • Current Quarter EPS Consensus Estimate: $-1.74 EPS
Additional Links:
Argos Therapeutics (NASDAQ:ARGS) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha